Compare MRNA & FTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRNA | FTAI |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | 985 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Corporate Leasing Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7B | 23.4B |
| IPO Year | 2018 | N/A |
| Metric | MRNA | FTAI |
|---|---|---|
| Price | $54.50 | $206.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $34.27 | ★ $274.67 |
| AVG Volume (30 Days) | ★ 6.0M | 1.6M |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $9.36 | $32.73 |
| Revenue Next Year | $15.43 | $51.41 |
| P/E Ratio | ★ N/A | $65.85 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $134.49 |
| 52 Week High | $85.60 | $323.51 |
| Indicator | MRNA | FTAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 40.08 |
| Support Level | $45.09 | $155.79 |
| Resistance Level | $59.52 | $269.05 |
| Average True Range (ATR) | 2.79 | 13.71 |
| MACD | -1.28 | -0.25 |
| Stochastic Oscillator | 20.90 | 46.83 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
FTAI Aviation Ltd is an independent engine maintenance platform focused on the CFM56-5B, CFM56-7B, and V2500 aircraft engines, which power the 737NG and A320ceo aircraft. The company repairs and rebuilds engines in its maintenance facilities and with joint venture partners, and sells or leases engines through its proprietary Maintenance, Repair and Exchange (MRE) model under the Aerospace Products segment, which earns maximum revenue from North America and develops, repairs/refurbishes, and sells aircraft engines and aftermarket components. It also operates an Aviation Leasing segment, owning and managing a portfolio of on- and off-lease aircraft and engines, including engine transfers for rebuilding and sales.